Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Sells $127,345.42 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Kevin Lee sold 9,038 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares of the company’s stock, valued at $6,974,916.34. The trade was a 1.79 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Bicycle Therapeutics Stock Down 0.1 %

NASDAQ BCYC traded down $0.01 on Monday, reaching $14.88. The stock had a trading volume of 289,310 shares, compared to its average volume of 435,603. Bicycle Therapeutics plc has a 12-month low of $12.17 and a 12-month high of $28.67. The stock has a fifty day moving average price of $19.27 and a two-hundred day moving average price of $21.86. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -4.52 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. During the same quarter in the previous year, the business earned ($1.26) EPS. The company’s quarterly revenue was down 50.0% compared to the same quarter last year. Sell-side analysts forecast that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BCYC. Assetmark Inc. purchased a new stake in Bicycle Therapeutics during the 3rd quarter worth approximately $34,000. GAMMA Investing LLC grew its stake in shares of Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after acquiring an additional 1,038 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Bicycle Therapeutics by 69.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after acquiring an additional 2,918 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after acquiring an additional 1,782 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Bicycle Therapeutics in the second quarter valued at $206,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on BCYC shares. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. Stephens initiated coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They set an “equal weight” rating and a $25.00 price objective on the stock. HC Wainwright cut their price objective on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research report on Monday, December 16th. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a report on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Bicycle Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $35.25.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.